MedTrace Logo

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

NCT01119768 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 305

Last updated 2012-09-28

Study results available
· View outcomes & findings →

Summary

To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.

Conditions

  • Non Erosive Reflux Disease
  • Chronic Gastritis

Interventions

DRUG

Esomeprazole

20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment

DRUG

Esomeprazole

20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up

Sponsors & Collaborators

Principal Investigators

  • Wenyu Guo · AstraZeneca China MC

  • Prof. Yuan Yaozong · Shanghai Jiaotong University, School of Medicine, Affiliated of Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119768 on ClinicalTrials.gov